CA2201628A1 - Parenteral pharmaceutical compositions containing gf120918a - Google Patents
Parenteral pharmaceutical compositions containing gf120918aInfo
- Publication number
- CA2201628A1 CA2201628A1 CA002201628A CA2201628A CA2201628A1 CA 2201628 A1 CA2201628 A1 CA 2201628A1 CA 002201628 A CA002201628 A CA 002201628A CA 2201628 A CA2201628 A CA 2201628A CA 2201628 A1 CA2201628 A1 CA 2201628A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- composition according
- safe
- effective amount
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Pharmaceutical compositions that prevent or minimize precipitation upon injection or infusion, comprising: a) a safe and therapeutically effective amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and its physiologically acceptable salts and solvates; b) a safe and effective amount of a surfactant; c) a buffer system; and d) a pharmaceutically acceptable carrier.
Description
FIEI,D OF THE INVF.~TION
The present Invention relates to novel pharmaceutical compositions that 5 are useful in ~r~v~nling malignant cells from becoming resistant to a diverse variety of chemotherapeutic agents.
BACKGROUND OF THE INVENTION
The multidrug-resistance inhibitor, chemirAlly known as N-{4-[2-1,2,3,4-10 tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carbox~mi~l~ and its physiologically acceptable salts and solvates is described and ~ e~ in World Patent Application WO 92/12132 filed in the name of Laboratires Glaxo S.A. and published July 23, 1992. Multidrug-resistanceis a process whereby tumor cells become resistant to structurally diverse 15 chemotherapeutic agents following exposure to treatment with anti-tumor drugs.
This acquired drug resistance can be a major obstacle in the clinical treatment and management of malignant disease. It has been shown that this type of resistance can be reversed by GF120918, resensitizing multidrug-resistant tumor ceIls to various chemotherapeutic agents. It has also been seen that certain tumors are 20 intrinsically multidrug-resistant and the use of multidrug-resistance inhibitors are also beneficial in treating tumors of this type.
GF120918A, the hydrochloride salt of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo 4 25 acridine carboxAmi~l~, to be safely and effectively administered to patients parenlerally by either intravenous injection or intravenous infusion must be adequately miscible in the blood. Therefore, any combination of the drug and thevarious excipients, in a liquid form, must be sllffl~iPntly compatible with the physiological composition of the blood to allow sufficient admixing. This mixing30 with the blood allows the compound to be distributed throughout the body in an unr~m~rk~hle fashion. However, problems exist with the parental administration of GF120918A due to the compounds poor solubility- GF120918A is a weak base and therefore exhibits a higher solubility at a pH less than about 4. Since the pH of the blood is approximately 7-4, the c~pound alone in solution precipitates upon 35 injection or infusion into the blood stream.
An object of the present Inventionis to provide a parenteral formulation that when injected or infused into the blood stream remains miscible and allows CA 0220l628 l997-04-02 W O 96/11007 PCTrUS95/12952 the active drug to be distributed throughout the body in an unremarkable fashion.
A further object of the present Invention is to provide a parenteral formulationand method of use that will improve or increase the efficacy of a chemotherapeutic agent or restore sensitivity of a tumor to chemotherapeutic 5 agent or reverse or reduce resistance of a tumor to a chemotherapeutic agent;
subsequently abating tumor cell multidrug-resistance and decreasing morbidity.
Publications such as In Vitro Method for l~etecting Precipitation of parenteral Forml~lAtion~ After Injections Journal of Pharmaceutical Sciences, Vol.
72, No. 9, September 1983; Pluronic SllrfActAnts Affecting Diazepam Solubility, Compatibility, and Adsorption From i.v. Admixture Solutions, Journal of Surface Sciences, Vol. 11, No. 4, 1988, Taiwan, Republic of China, Precipitation of the Renin Inhibitor Ditekiren Upon iv Infusion: in Vitro Studies and Their Relation~l~ip to in VivQ Precipitation in the Cynomolgus Monkey Pharmaceutical Research, Vol. 8, No. 1, 1991; Intravenous premedication with diazepam A
comparison between two vehicles Anesthesia, 1984, Vol. 39, p. 879-882;
Precipitation of Solub;1i7~d Drugs due to Injection or Dilution Drug Intelligence and t~linic~l Pharmacy, Vol. 11, July 77; and U.S. Patents 4 205 089 and 4 296 131 issued May 27, 1980 and October 20, 1981 both to Ladage et al., teach how to increase the solubility of a compound in a formulation. These publications advocate the use of: cosolvents, complexing agents, hydrotropic agents, liposomes, fat ~m~ ions, polyaphrons, dimethylsulfoxide and surfactants. However, even though GF120918A is soluble in the standardized formulations utilized for parenlelal administration, precipitation nevertheless occurs upon injection or infusion into the blood stream. This precipitation on infusion occurs as the formulation, a weak base, mixes within the pH neutral blood stream. The novel compositions of the present Invention maintain solubility within the blood stream and prevent precipitation of the drug upon injection or infusion into theblood stream.
SUMMARY OF THE INVENTION
The present Invention relates to pharmaceutical compositions that prevent or minimize precipitation upon injection or infusion; comprising:
a) a safe and therapeutically effective amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and its physiologically acceptable salts and solvates;
b) a safe and effective amount of a surfactant;
c) a buffer; and d) a p~ArmAceutically acceptable carrier or diluent.
D~AT~.Fn DESCRII~IlQN OF IHE INVENTION
By "safe and therapeutically effective amount," as used herein, means a sufficient amount of a drug or pharmaceutical agent to abate or reverse a multidrug-resistance response of a tissue, system or animal that is being sought by the researcher or clinician without ~Arming the tissues of a mammal, including ahuman to which the drug is administered.
The compositions of the present Invention employ a safe and therapeutically effective amount of the compound N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl] -phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) and its physiologically acceptable salts and solvates, a safe and effective amount of a surfactant, a safe and effective amount of a buffer and a carrier or diluent suitable for pharmaceutical use. These compositions are suitable for administration to mAmmAl.s, including humans through various parenleral routes. These various parenteral routes particularly include both intravenous bolus injection and intravenous infusion.
Persons who treat cancer and other diseases which become resistant to chemotherapeutic, anti-tumor compounds would use the compositions of the present Invention to resensitize multidrug-resistant cells to chemotherapeutic agents thus abating multidrug-resistance. Therefore, compositions of the presentInvention may be administered in conjunction with an antitumor drug.
Examples of suitable antitumor drugs for use in conjunction with compositions ofthe present include, but are not limited to, Vinca AlkAloifls (e.g. vincristine,vinblastine and vinorelbine, anthracyclines (e.g. daunorubincin, doxorubicin andaclarubincin, taxol, and derivatives thereof (e.g. taxotere), podophyllotixins (e.g.
etoposide and VP16), mitoxantrone, actinomycin, colchicine, gramidine D, cisplatin, cyclophosphamide, amsacrine or any other chemotherapeutic, antitumor type compounds.
Compositions of the present Invention while being given in conjunction with an antitumor drug, could also be given simultaneously with an anti-tumor drug. This type of administration is acceptable as long as the components of thecomposition of the present Invention and any antitumor compound given simultaneously are both physically and chemically compatible. In this instance W O 96tllO07 PCTrUS95/12952 "simultaneously" means, sequentially with little or no delay or given together from a common single container where the composition of the present Invention and the antitumor drug are physically mixed.
The ~er~ic~Al community, particularly oncologists and other me-1icAl professionals who treat persons afflicted with tumor disease recognize that patients suffer various adverse side-effects from the administration of chemo~erapeutic anti-tumor drugs. One of the most serious side effects produced by chemotherapeutic anti-tumor drugs is nausea and vomiting. Nausea and vomiting can result in severe consequences leading to increased morbidity and mortality. Compositions of the present Invention may also be administered with various drug formulations to combat side-effects produced by anti-tumor chemotherapy. These other drug formulations may be given either simultaneously or in conjunction with formulations of the present Invention. If given simllltAneously by either being admixed in the same syringe for injection or admixed in the same intravenous bag or bottle for infusion the various formulations must be both physically and chemically compatible with compositions of the present Invention. If, however, the formulation given in conjunction with compositions of the present Invention or given together at the same time, but from a different container or is given by another route or given intravenously either prior to or subsequently to compositions of the present Invention physical and ch~micAl reactivity should not be problematic.
Parenteral compositions of the present Invention must be in a sterile form.
Any of the various methods known to persons skilled in the art employed to prepare sterile parenteral preparations that will nct degrade components of the present Invention are suitable for use in the compositions sterile preparation.
Parenleial compositions of the present Invention may be packaged, produced or contained in packaging materials such as single use ampoules, vials or intravenous bottles or bags or alternatively in multidose or multiuse vials or containers.
Compositions of the present Invention may also be packaged as articles of manufacture comprising a safe and therapeutically effective amount of GF120918 and its physiologically acceptable salts and solvates; a safe and effective amount of a surfactant; a buffer; and a pharmaceutically acceptable carrier or diluent, packaged as described above. The packaging material may also have labeling and information relating to the pharmaceutical composition printed thereon.
.
Additionally an article of manufacture may have a brochure, report, notice, pamphlet, or leaflet containing product information. This form of pharmaceuticalproduct information is sometimes, in the pharmaceutical industry, called the "package insert." A package insert may be attached to or included with a 5 ph~rmAceutical artide of manufacture. The package insert and any article of manufacture labeling provides information relating to the pharmaceutical composition. This information and labeling provides various forms of information tltili7e-1 by health care professior~Al~ and patients that describes the composition, its dosage and various other parameters required by regulatory 10 agencies, such as the United States Food and Drug Administration.
The pH of the present compositions range from about 1 to about 5, particularly from about 2.5 to about 4. The essential, as well as possible optional components of the compositions of the present Invention, are described in the 15 following paragraphs.
Essential Components One of the essential components of the present Invention is GF120918 and its physiologically acceptable salts and solvates, described in International Patent 20 Application WO 92/12132 published 23 July 1992. GF120918 is an acridine derivative that is able to reverse or reduce resistance to, increase or restore sensitivity to or improve or increase the efficacy of an chemotherapeutic agent or agents.
The amount of GF120918 administered to prevent, abate or reverse multidrug resistance in a m~mm~l including a human will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general, however, doses employed for adult human treatment will typically be in the range of about 1 mg to about 10 gm per day, particularly from about 10 mg toabout 1 gm per day and more particularly from about 25 mg to about 750 mg per day. The desired dose may conveniently be presented in a single dose or as divided doses administered at a~rv~liate intervals, for example as two, three, four or more sub-doses per day.
Another of the essential components of by the present Invention is a surface-active agent or a mixture of compatible surface-active agents, sometimesreferred to as surfactants. Any compatible surface-active agent is sufficient for use in the present Invention, however, nonionic surface-active agents are particularly suitable.
Nonionic surface-active agents are particularly suitable in compositions of 5 the present Invention and can be broadly defined as compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkylaromatic in nature.
Examples of suitable nonionic surfactants include, but are not limite-l to:
pluronics, polyethylene oxide condensates of alkyl phenols, products derived from 10 the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene ~i~mine, ethylene oxide condensates of aliphatic alcohol's, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides and mixtures of such materials.
The surface-active agent or mixtures of compatible surface-active agents can be present in the compositions of the present Invention from about 0.05% to about 20.0%, parti~llArly from about 0.1% to about 10.0% and most particularly from about 0.5% to about 5.0% by weight of the total composition.
The surface-active agents best suited for inclusion into the present composition are: polyethylene glycol 660 hydroxystearate (SOLUTOL(~) HS-15), polyoxyethylene castor oil derivatives (CREMOPHOR(~) EL, RH40, and RH60), poloxamer, polyoxyethylene aL~yl ethers (CETOMACROGOL(g) 1000) and polyoxyethylene sorbitan fatty acid esters (POLYSORBATE(3) 20, 40, 60, and 80 and TWEEN~) 20, 40, 60 and 80). In particular polyethylene glycol 660 hydroxystearate, polyethylene glycol, polyoxyethylene castor oil derivatives and polyoxyethylene sorbitan fatty acid esters are useful in compositions of the present Invention.
Another essential component of the present Invention is a buffer or mixture of buffers. Buffers are compounds or mixtures of compounds which if present in a solution resist changes in the pH of the solution upon the addition of small quantities of acids or bases. Further information about buffers can be found in Remington's p~ArmAceutical Sciences, p. 243 - 45 17th ed. (1985). Examples ofbuffers suitable for use in compositions of the present Invention include: acetate, phosphate and glutAmAte The last essential component of the present Invention is a suitable carrier or diluent that provides an appropriate vehicle for parenteral delivery of the WO 96/11007 PCT/US9~/12952 composition without the introduction of untoward side-effects. Persons skilled in the art will quickly realize that any carrier or diluent intended for parenteraladministration that is compatible with the essential and any optional componentsof the present Invention will be suitable. Examples of suitable carriers and diluents include, but are not limited to: dextrose 5% in water and sterile water for injection.
Optional Components In ~d~lition to the above described essential components, the compositions of the present Invention can contain a variety of optional parenteral conventional components known to persons skilled in the art. Any optional components included in compositions of the present Invention must be physically and chemically compatible with the essential components of the present Invention.
Optional components include, but are not limited to: cosolvents, including but not limited to, polyethylene glycol (PEG) grades 200 to 600, propylene glycol (1,2-propanediol), ethanol and glycerin, preservatives and agents that adjust isotonicity and osmolality. Further information concerning preservatives and agents to adjust isotonicity and osmolAlity can be found in Remington's Pharmaceutical Sciences, p. 1278 - 1280, 1455 - 1472, 17th ed. (1985) Optional components may also include other drugs or combinations of drugs that are physically and c~emic~lly compatible with compositions of the present Invention. Possible optional additional drugs include, but are not limited to antitumor chemotherapeutic agents, antinausents including, serotonin 5-HT3 receptor antagonists such as ondansetron and granisetron and various other antinausents such as prochlorperazine, chlorpromazine, perphenazine, thiethylperazine, trifluprom~7.ine, droperidol, methochlopramide, trimethobenzamide, dronabinol, pherergan, nabilone and methylpredinisone.
Other additional optional drugs include: antibiotics, antidepressants, antiulcercompounds, analgesics, anticholornergics, antivirals and a myriad of other drugssuitable to treat conditions that also require the administration of compositions of the present Invention.
METHOD OF MANUFACTURE
The compositions of the present Invention can be made using methods and techniques that are commonly employed in preparing parenteral preparations within the pharmaceutical industry. Remington's Pharmaceutical Sciences, p.
1518 - 1541, 17th ed. (1985).
COMPOSII~ON USE
Compositions of the present Invention in their method aspect involves administering to a mAmmAl, including a human a safe and effective amount of the compositions of the present Invention described herein. These safe and 5 effective amounts will vary based on the type and size of mAmn~l being treated and the results wished to be obtained.
EXAMpT.F~
The following examples further describe and demonstrate particular 10 embo~liments within the scope of the present Invention. The examples are given solely for illustration and are not to be construed as limitations as many variations are possible without departing from the Invention's spirit and scope.
Fxample I
Ir~gre~ nts Amounts GP120918A 0.53 mg (-~1A~;A1 acetic acid 2.87 microliters TWEEN 80~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Preparation 100 mL of 0.5 mg GF120918A/mL Intravenous Infusion, 0.05M Acetate, pH
3.75, 1% v/v TWEEN 80, qs with 5% Dextrose in water.
Pipette 286.5 IlL of glacial acetic acid into a beaker and add approximately 50 mL of D5W. Weigh 1.08 g of polysorbate 80 and add to the beaker with glacial acetic acid and D5W. Using a spatula and rinsing with D5W if necessary, dispersethe polysorbate 80 by stirring. Weigh 53.2 mg of GF120918A and dissolve it in the above solution. Add additional D5W until a total volume of approximately 98 mL
is achieved. Dissolve 5 g of sodium hydroxide in 30 mL of distilled, deionized water in a separate beaker. Add the sodium hydroxide solution dropwise with stirring to the solution until a pH of 3.75 is achieved. Pour the resulting solution into a 100 mL volumetric flask and q.s. to 100 mL with D5W. Stir or shake the solution to ensure homogeneity. Filter the final solution through a 0.22 ~1 filter to ensure sterility.
W O96111007 PCT~US95/12952 ~mple TT
GF120918A 0.53 mg l acetic acid 2.87 microliters CREMOPHOR EL~ 10 microliters Sodium Hydroxide adjustto pH3.75 5% Dextrose in water (USP) qs to 1 mL
~xample m GF120918A 0.53 mg Glacial acetic acid 2.87 microliters CREMOPHOR RH40~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
~rnple IV
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters CREMOPHOR RH60(~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Fxample V
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters SOLUTOL H~15(E~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Example VI
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters TWEEN 60(~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Example VII
GF120918A 3.19 mg PEG 300 0.4 mL
TWEEN 80(~) 100 microliters Glacialacetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
F.x~mple V~TT
GF120918A 3.19 mg PEG 300 0.4 mL
CREMOPHOR EL~g) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
T~xample IX
GF120918A 3.19 mg PEG 300 0.4 mL
TWEEN 60~) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
Fxample X
GF120918A 3.19 mg PEG 300 0.4 mL
CREMOPHOR RH40(~) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
Example ~T
GF120918A 3.19 mg PEG 300 0.4 mL
CREMOPHOR RH60(~) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
Example XTT
GF120918A 3.19 mg PEG300 0.4 mL
SOLUTOL HS-15(g) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
=
W O96/11007 PCTrUS95/12952 R~Ample X~TT
GF120918A 3.19 mg PEG 300 0.4 mL
. TWEEN 20~) 100 microliters Glacialacetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
RxAm,ple XTV
GF120918A 3.19 mg PEG 300 0.4 mL
TWEEN 40~) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
Rxample XV
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters TWEEN 20(~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
ExAmple XVI
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters TWEEN 40(g) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
The present Invention relates to novel pharmaceutical compositions that 5 are useful in ~r~v~nling malignant cells from becoming resistant to a diverse variety of chemotherapeutic agents.
BACKGROUND OF THE INVENTION
The multidrug-resistance inhibitor, chemirAlly known as N-{4-[2-1,2,3,4-10 tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carbox~mi~l~ and its physiologically acceptable salts and solvates is described and ~ e~ in World Patent Application WO 92/12132 filed in the name of Laboratires Glaxo S.A. and published July 23, 1992. Multidrug-resistanceis a process whereby tumor cells become resistant to structurally diverse 15 chemotherapeutic agents following exposure to treatment with anti-tumor drugs.
This acquired drug resistance can be a major obstacle in the clinical treatment and management of malignant disease. It has been shown that this type of resistance can be reversed by GF120918, resensitizing multidrug-resistant tumor ceIls to various chemotherapeutic agents. It has also been seen that certain tumors are 20 intrinsically multidrug-resistant and the use of multidrug-resistance inhibitors are also beneficial in treating tumors of this type.
GF120918A, the hydrochloride salt of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo 4 25 acridine carboxAmi~l~, to be safely and effectively administered to patients parenlerally by either intravenous injection or intravenous infusion must be adequately miscible in the blood. Therefore, any combination of the drug and thevarious excipients, in a liquid form, must be sllffl~iPntly compatible with the physiological composition of the blood to allow sufficient admixing. This mixing30 with the blood allows the compound to be distributed throughout the body in an unr~m~rk~hle fashion. However, problems exist with the parental administration of GF120918A due to the compounds poor solubility- GF120918A is a weak base and therefore exhibits a higher solubility at a pH less than about 4. Since the pH of the blood is approximately 7-4, the c~pound alone in solution precipitates upon 35 injection or infusion into the blood stream.
An object of the present Inventionis to provide a parenteral formulation that when injected or infused into the blood stream remains miscible and allows CA 0220l628 l997-04-02 W O 96/11007 PCTrUS95/12952 the active drug to be distributed throughout the body in an unremarkable fashion.
A further object of the present Invention is to provide a parenteral formulationand method of use that will improve or increase the efficacy of a chemotherapeutic agent or restore sensitivity of a tumor to chemotherapeutic 5 agent or reverse or reduce resistance of a tumor to a chemotherapeutic agent;
subsequently abating tumor cell multidrug-resistance and decreasing morbidity.
Publications such as In Vitro Method for l~etecting Precipitation of parenteral Forml~lAtion~ After Injections Journal of Pharmaceutical Sciences, Vol.
72, No. 9, September 1983; Pluronic SllrfActAnts Affecting Diazepam Solubility, Compatibility, and Adsorption From i.v. Admixture Solutions, Journal of Surface Sciences, Vol. 11, No. 4, 1988, Taiwan, Republic of China, Precipitation of the Renin Inhibitor Ditekiren Upon iv Infusion: in Vitro Studies and Their Relation~l~ip to in VivQ Precipitation in the Cynomolgus Monkey Pharmaceutical Research, Vol. 8, No. 1, 1991; Intravenous premedication with diazepam A
comparison between two vehicles Anesthesia, 1984, Vol. 39, p. 879-882;
Precipitation of Solub;1i7~d Drugs due to Injection or Dilution Drug Intelligence and t~linic~l Pharmacy, Vol. 11, July 77; and U.S. Patents 4 205 089 and 4 296 131 issued May 27, 1980 and October 20, 1981 both to Ladage et al., teach how to increase the solubility of a compound in a formulation. These publications advocate the use of: cosolvents, complexing agents, hydrotropic agents, liposomes, fat ~m~ ions, polyaphrons, dimethylsulfoxide and surfactants. However, even though GF120918A is soluble in the standardized formulations utilized for parenlelal administration, precipitation nevertheless occurs upon injection or infusion into the blood stream. This precipitation on infusion occurs as the formulation, a weak base, mixes within the pH neutral blood stream. The novel compositions of the present Invention maintain solubility within the blood stream and prevent precipitation of the drug upon injection or infusion into theblood stream.
SUMMARY OF THE INVENTION
The present Invention relates to pharmaceutical compositions that prevent or minimize precipitation upon injection or infusion; comprising:
a) a safe and therapeutically effective amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and its physiologically acceptable salts and solvates;
b) a safe and effective amount of a surfactant;
c) a buffer; and d) a p~ArmAceutically acceptable carrier or diluent.
D~AT~.Fn DESCRII~IlQN OF IHE INVENTION
By "safe and therapeutically effective amount," as used herein, means a sufficient amount of a drug or pharmaceutical agent to abate or reverse a multidrug-resistance response of a tissue, system or animal that is being sought by the researcher or clinician without ~Arming the tissues of a mammal, including ahuman to which the drug is administered.
The compositions of the present Invention employ a safe and therapeutically effective amount of the compound N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl] -phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) and its physiologically acceptable salts and solvates, a safe and effective amount of a surfactant, a safe and effective amount of a buffer and a carrier or diluent suitable for pharmaceutical use. These compositions are suitable for administration to mAmmAl.s, including humans through various parenleral routes. These various parenteral routes particularly include both intravenous bolus injection and intravenous infusion.
Persons who treat cancer and other diseases which become resistant to chemotherapeutic, anti-tumor compounds would use the compositions of the present Invention to resensitize multidrug-resistant cells to chemotherapeutic agents thus abating multidrug-resistance. Therefore, compositions of the presentInvention may be administered in conjunction with an antitumor drug.
Examples of suitable antitumor drugs for use in conjunction with compositions ofthe present include, but are not limited to, Vinca AlkAloifls (e.g. vincristine,vinblastine and vinorelbine, anthracyclines (e.g. daunorubincin, doxorubicin andaclarubincin, taxol, and derivatives thereof (e.g. taxotere), podophyllotixins (e.g.
etoposide and VP16), mitoxantrone, actinomycin, colchicine, gramidine D, cisplatin, cyclophosphamide, amsacrine or any other chemotherapeutic, antitumor type compounds.
Compositions of the present Invention while being given in conjunction with an antitumor drug, could also be given simultaneously with an anti-tumor drug. This type of administration is acceptable as long as the components of thecomposition of the present Invention and any antitumor compound given simultaneously are both physically and chemically compatible. In this instance W O 96tllO07 PCTrUS95/12952 "simultaneously" means, sequentially with little or no delay or given together from a common single container where the composition of the present Invention and the antitumor drug are physically mixed.
The ~er~ic~Al community, particularly oncologists and other me-1icAl professionals who treat persons afflicted with tumor disease recognize that patients suffer various adverse side-effects from the administration of chemo~erapeutic anti-tumor drugs. One of the most serious side effects produced by chemotherapeutic anti-tumor drugs is nausea and vomiting. Nausea and vomiting can result in severe consequences leading to increased morbidity and mortality. Compositions of the present Invention may also be administered with various drug formulations to combat side-effects produced by anti-tumor chemotherapy. These other drug formulations may be given either simultaneously or in conjunction with formulations of the present Invention. If given simllltAneously by either being admixed in the same syringe for injection or admixed in the same intravenous bag or bottle for infusion the various formulations must be both physically and chemically compatible with compositions of the present Invention. If, however, the formulation given in conjunction with compositions of the present Invention or given together at the same time, but from a different container or is given by another route or given intravenously either prior to or subsequently to compositions of the present Invention physical and ch~micAl reactivity should not be problematic.
Parenteral compositions of the present Invention must be in a sterile form.
Any of the various methods known to persons skilled in the art employed to prepare sterile parenteral preparations that will nct degrade components of the present Invention are suitable for use in the compositions sterile preparation.
Parenleial compositions of the present Invention may be packaged, produced or contained in packaging materials such as single use ampoules, vials or intravenous bottles or bags or alternatively in multidose or multiuse vials or containers.
Compositions of the present Invention may also be packaged as articles of manufacture comprising a safe and therapeutically effective amount of GF120918 and its physiologically acceptable salts and solvates; a safe and effective amount of a surfactant; a buffer; and a pharmaceutically acceptable carrier or diluent, packaged as described above. The packaging material may also have labeling and information relating to the pharmaceutical composition printed thereon.
.
Additionally an article of manufacture may have a brochure, report, notice, pamphlet, or leaflet containing product information. This form of pharmaceuticalproduct information is sometimes, in the pharmaceutical industry, called the "package insert." A package insert may be attached to or included with a 5 ph~rmAceutical artide of manufacture. The package insert and any article of manufacture labeling provides information relating to the pharmaceutical composition. This information and labeling provides various forms of information tltili7e-1 by health care professior~Al~ and patients that describes the composition, its dosage and various other parameters required by regulatory 10 agencies, such as the United States Food and Drug Administration.
The pH of the present compositions range from about 1 to about 5, particularly from about 2.5 to about 4. The essential, as well as possible optional components of the compositions of the present Invention, are described in the 15 following paragraphs.
Essential Components One of the essential components of the present Invention is GF120918 and its physiologically acceptable salts and solvates, described in International Patent 20 Application WO 92/12132 published 23 July 1992. GF120918 is an acridine derivative that is able to reverse or reduce resistance to, increase or restore sensitivity to or improve or increase the efficacy of an chemotherapeutic agent or agents.
The amount of GF120918 administered to prevent, abate or reverse multidrug resistance in a m~mm~l including a human will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general, however, doses employed for adult human treatment will typically be in the range of about 1 mg to about 10 gm per day, particularly from about 10 mg toabout 1 gm per day and more particularly from about 25 mg to about 750 mg per day. The desired dose may conveniently be presented in a single dose or as divided doses administered at a~rv~liate intervals, for example as two, three, four or more sub-doses per day.
Another of the essential components of by the present Invention is a surface-active agent or a mixture of compatible surface-active agents, sometimesreferred to as surfactants. Any compatible surface-active agent is sufficient for use in the present Invention, however, nonionic surface-active agents are particularly suitable.
Nonionic surface-active agents are particularly suitable in compositions of 5 the present Invention and can be broadly defined as compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkylaromatic in nature.
Examples of suitable nonionic surfactants include, but are not limite-l to:
pluronics, polyethylene oxide condensates of alkyl phenols, products derived from 10 the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene ~i~mine, ethylene oxide condensates of aliphatic alcohol's, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides and mixtures of such materials.
The surface-active agent or mixtures of compatible surface-active agents can be present in the compositions of the present Invention from about 0.05% to about 20.0%, parti~llArly from about 0.1% to about 10.0% and most particularly from about 0.5% to about 5.0% by weight of the total composition.
The surface-active agents best suited for inclusion into the present composition are: polyethylene glycol 660 hydroxystearate (SOLUTOL(~) HS-15), polyoxyethylene castor oil derivatives (CREMOPHOR(~) EL, RH40, and RH60), poloxamer, polyoxyethylene aL~yl ethers (CETOMACROGOL(g) 1000) and polyoxyethylene sorbitan fatty acid esters (POLYSORBATE(3) 20, 40, 60, and 80 and TWEEN~) 20, 40, 60 and 80). In particular polyethylene glycol 660 hydroxystearate, polyethylene glycol, polyoxyethylene castor oil derivatives and polyoxyethylene sorbitan fatty acid esters are useful in compositions of the present Invention.
Another essential component of the present Invention is a buffer or mixture of buffers. Buffers are compounds or mixtures of compounds which if present in a solution resist changes in the pH of the solution upon the addition of small quantities of acids or bases. Further information about buffers can be found in Remington's p~ArmAceutical Sciences, p. 243 - 45 17th ed. (1985). Examples ofbuffers suitable for use in compositions of the present Invention include: acetate, phosphate and glutAmAte The last essential component of the present Invention is a suitable carrier or diluent that provides an appropriate vehicle for parenteral delivery of the WO 96/11007 PCT/US9~/12952 composition without the introduction of untoward side-effects. Persons skilled in the art will quickly realize that any carrier or diluent intended for parenteraladministration that is compatible with the essential and any optional componentsof the present Invention will be suitable. Examples of suitable carriers and diluents include, but are not limited to: dextrose 5% in water and sterile water for injection.
Optional Components In ~d~lition to the above described essential components, the compositions of the present Invention can contain a variety of optional parenteral conventional components known to persons skilled in the art. Any optional components included in compositions of the present Invention must be physically and chemically compatible with the essential components of the present Invention.
Optional components include, but are not limited to: cosolvents, including but not limited to, polyethylene glycol (PEG) grades 200 to 600, propylene glycol (1,2-propanediol), ethanol and glycerin, preservatives and agents that adjust isotonicity and osmolality. Further information concerning preservatives and agents to adjust isotonicity and osmolAlity can be found in Remington's Pharmaceutical Sciences, p. 1278 - 1280, 1455 - 1472, 17th ed. (1985) Optional components may also include other drugs or combinations of drugs that are physically and c~emic~lly compatible with compositions of the present Invention. Possible optional additional drugs include, but are not limited to antitumor chemotherapeutic agents, antinausents including, serotonin 5-HT3 receptor antagonists such as ondansetron and granisetron and various other antinausents such as prochlorperazine, chlorpromazine, perphenazine, thiethylperazine, trifluprom~7.ine, droperidol, methochlopramide, trimethobenzamide, dronabinol, pherergan, nabilone and methylpredinisone.
Other additional optional drugs include: antibiotics, antidepressants, antiulcercompounds, analgesics, anticholornergics, antivirals and a myriad of other drugssuitable to treat conditions that also require the administration of compositions of the present Invention.
METHOD OF MANUFACTURE
The compositions of the present Invention can be made using methods and techniques that are commonly employed in preparing parenteral preparations within the pharmaceutical industry. Remington's Pharmaceutical Sciences, p.
1518 - 1541, 17th ed. (1985).
COMPOSII~ON USE
Compositions of the present Invention in their method aspect involves administering to a mAmmAl, including a human a safe and effective amount of the compositions of the present Invention described herein. These safe and 5 effective amounts will vary based on the type and size of mAmn~l being treated and the results wished to be obtained.
EXAMpT.F~
The following examples further describe and demonstrate particular 10 embo~liments within the scope of the present Invention. The examples are given solely for illustration and are not to be construed as limitations as many variations are possible without departing from the Invention's spirit and scope.
Fxample I
Ir~gre~ nts Amounts GP120918A 0.53 mg (-~1A~;A1 acetic acid 2.87 microliters TWEEN 80~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Preparation 100 mL of 0.5 mg GF120918A/mL Intravenous Infusion, 0.05M Acetate, pH
3.75, 1% v/v TWEEN 80, qs with 5% Dextrose in water.
Pipette 286.5 IlL of glacial acetic acid into a beaker and add approximately 50 mL of D5W. Weigh 1.08 g of polysorbate 80 and add to the beaker with glacial acetic acid and D5W. Using a spatula and rinsing with D5W if necessary, dispersethe polysorbate 80 by stirring. Weigh 53.2 mg of GF120918A and dissolve it in the above solution. Add additional D5W until a total volume of approximately 98 mL
is achieved. Dissolve 5 g of sodium hydroxide in 30 mL of distilled, deionized water in a separate beaker. Add the sodium hydroxide solution dropwise with stirring to the solution until a pH of 3.75 is achieved. Pour the resulting solution into a 100 mL volumetric flask and q.s. to 100 mL with D5W. Stir or shake the solution to ensure homogeneity. Filter the final solution through a 0.22 ~1 filter to ensure sterility.
W O96111007 PCT~US95/12952 ~mple TT
GF120918A 0.53 mg l acetic acid 2.87 microliters CREMOPHOR EL~ 10 microliters Sodium Hydroxide adjustto pH3.75 5% Dextrose in water (USP) qs to 1 mL
~xample m GF120918A 0.53 mg Glacial acetic acid 2.87 microliters CREMOPHOR RH40~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
~rnple IV
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters CREMOPHOR RH60(~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Fxample V
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters SOLUTOL H~15(E~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Example VI
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters TWEEN 60(~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Example VII
GF120918A 3.19 mg PEG 300 0.4 mL
TWEEN 80(~) 100 microliters Glacialacetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
F.x~mple V~TT
GF120918A 3.19 mg PEG 300 0.4 mL
CREMOPHOR EL~g) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
T~xample IX
GF120918A 3.19 mg PEG 300 0.4 mL
TWEEN 60~) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
Fxample X
GF120918A 3.19 mg PEG 300 0.4 mL
CREMOPHOR RH40(~) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
Example ~T
GF120918A 3.19 mg PEG 300 0.4 mL
CREMOPHOR RH60(~) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
Example XTT
GF120918A 3.19 mg PEG300 0.4 mL
SOLUTOL HS-15(g) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
=
W O96/11007 PCTrUS95/12952 R~Ample X~TT
GF120918A 3.19 mg PEG 300 0.4 mL
. TWEEN 20~) 100 microliters Glacialacetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
RxAm,ple XTV
GF120918A 3.19 mg PEG 300 0.4 mL
TWEEN 40~) 100 microliters Glacial acetic acid 17.2 microliters Sodium Hydroxide adjust to pH 3.5 Water for Injection (USP) qs to 1 mL
Rxample XV
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters TWEEN 20(~) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
ExAmple XVI
GF120918A 0.53 mg Glacial acetic acid 2.87 microliters TWEEN 40(g) 10 microliters Sodium Hydroxide adjust to pH 3.75 5% Dextrose in water (USP) qs to 1 mL
Claims (20)
1. A pharmaceutical composition that prevents or minimizes precipitation of the compositions active ingredient upon parenteral administration; comprising:
a) a safe and effective amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and its physiologically acceptable salts and solvates;
b) a safe and effective amount of a surfactant;
c) a buffer; and d) a pharmaceutically acceptable carrier or diluent.
a) a safe and effective amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide and its physiologically acceptable salts and solvates;
b) a safe and effective amount of a surfactant;
c) a buffer; and d) a pharmaceutically acceptable carrier or diluent.
2. A pharmaceutical composition according to Claim 1 wherein the pH is from about 1 to about 5.
3. A pharmaceutical composition according to Claim 2 wherein the amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide or its physiologically acceptable, salts and solvates is from about 1 mg to about 10 gm.
4. A pharmaceutical composition according to Claim 3 wherein the surfactant is selected from the group consisting of: polyethylene glycol 660 hydroxystearate, polyoxyethylene castor oil derivatives, poloxamer, polyoxyethylene alkyl ethers,polyoxyethylene sorbitan fatty acid esters, polyethylene glycol, propylene glycol, ethanol and glycerin.
5. A pharmaceutical composition according to Claim 4 wherein the amount of surfactant is from about 0.5% to about 5%.
6. A pharmaceutical composition according to Claim 5 wherein the buffer is selected from the group consisting of: acetate, phosphate and glutamate.
7. A pharmaceutical composition according to Claim 6 wherein the amount of the buffer is from about 0.005% to about 0.5%.
8. A pharmaceutical composition according to Claim 7 wherein the pharmaceutically acceptable carrier or diluent is a sterile solution suitable for parenteral administration, selected from the group consisting of: dextrose 5% in water or sterile water for injection.
9. A pharmaceutical composition according to Claim 1 containing an additional buffer.
10. A pharmaceutical composition according to Claim 9 wherein the additional buffer is selected from the group consisting of: acetate, phosphate and glutamate.
11. A pharmaceutical composition according to Claim 1 additionally containing a safe and effective amount of a cosolvent.
12. A pharmaceutical composition according to Claim 11 wherein the cosolvent is selected from the group consisting of: polyethylene glycol, propylene glycol (1,2-propanediol), ethanol and glycerin.
13. A pharmaceutical composition according to Claim 1 additionally containing a safe and effective amount of and additional drug substance.
14. A pharmaceutical composition according to Claim 13 wherein the safe and effective amount of the additional drug substance is selected from the group consisting of: antinausents, antibiotics, antidepressants, antiulcer compounds, analgesics, anticholornergics and antivirals.
15. A pharmaceutical composition according to Claim 14 wherein the safe and effective amount of the additional drug substance is an antinausent selected from the group consisting of: serotonin 5-HT3 receptor antagonists, prochlorperazine,chlorpromazine, perphenazine, thiethylperazine, triflupromazine, droperidol, methochlopramide, trimethobenzamide, dronabinol, pherergan, nabilone and methylpredinisone.
16. A pharmaceutical composition according to Claim 15 wherein the safe and effective amount of the additional drug substance is a serotonin 5-HT3 receptor antagonist.
17. A method of reversing, reducing or inhibiting multidrug-resistance or increasing or restoring sensitivity to a tumor by administering a safe and effective amount of a composition according to Claim 1.
18. A method according to Claim 18 wherein the composition is administered as a parenteral injection or parenteral infusion.
19. An article of manufacture comprising:
a) packaging material; and b) a pharmaceutical composition contained within the packaging material, wherein the pharmaceutical composition prevents or minimizes precipitation of the compositions active ingredient upon injection or infusion, comprising:
i) a safe and therapeutically effective amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo4-acridine carboxamide and its physiologically acceptable salts and solvates;
ii) a safe and effective amount of a surfactant;
iii) a buffer; and iv) a pharmaceutically acceptable carrier or diluent.
a) packaging material; and b) a pharmaceutical composition contained within the packaging material, wherein the pharmaceutical composition prevents or minimizes precipitation of the compositions active ingredient upon injection or infusion, comprising:
i) a safe and therapeutically effective amount of N-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo4-acridine carboxamide and its physiologically acceptable salts and solvates;
ii) a safe and effective amount of a surfactant;
iii) a buffer; and iv) a pharmaceutically acceptable carrier or diluent.
20. An article of manufacture of Claim 19 additionally comprising: a brochure containing product information.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31830894A | 1994-10-05 | 1994-10-05 | |
| US08/318,308 | 1994-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2201628A1 true CA2201628A1 (en) | 1996-04-18 |
Family
ID=23237614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002201628A Abandoned CA2201628A1 (en) | 1994-10-05 | 1995-10-04 | Parenteral pharmaceutical compositions containing gf120918a |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0784474A2 (en) |
| JP (1) | JPH10507177A (en) |
| KR (1) | KR970705997A (en) |
| AU (1) | AU702519B2 (en) |
| BR (1) | BR9509251A (en) |
| CA (1) | CA2201628A1 (en) |
| CZ (1) | CZ104197A3 (en) |
| HU (1) | HUT77883A (en) |
| NZ (1) | NZ295546A (en) |
| PL (1) | PL319511A1 (en) |
| RU (1) | RU2157687C2 (en) |
| WO (1) | WO1996011007A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| GB9710612D0 (en) * | 1997-05-23 | 1997-07-16 | Glaxo Group Ltd | Synthesis of acridine derivatives |
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
| SK4782001A3 (en) | 1998-10-08 | 2001-11-06 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| AT408186B (en) * | 1998-12-15 | 2001-09-25 | Sanochemia Pharmazeutika Ag | AQUEOUS PREPARATION OF BETA CAROTINE |
| DK1189637T3 (en) | 1999-05-17 | 2006-12-11 | Cancer Res Ventures Ltd | Products to improve the bioavailability of orally administered drugs |
| US6521635B1 (en) | 2000-01-20 | 2003-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of MXR transport by acridine derivatives |
| JP2004501955A (en) * | 2000-06-30 | 2004-01-22 | アイネックス ファーマシューティカルズ コーポレイション | Liposomal anti-neoplastic agents and uses thereof |
| US7122201B2 (en) | 2001-06-28 | 2006-10-17 | Baxter International Inc. | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using surfactants and amino acids |
| KR100866728B1 (en) * | 2004-11-12 | 2008-11-03 | 주식회사종근당 | The injection of tacrolimus |
| FR2948568B1 (en) * | 2009-07-30 | 2012-08-24 | Sanofi Aventis | PHARMACEUTICAL FORMULATION |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL168202B1 (en) * | 1991-01-11 | 1996-01-31 | Glaxo Lab Sa | Method of obtaining novel derivatives of acridine |
-
1995
- 1995-10-04 WO PCT/US1995/012952 patent/WO1996011007A1/en not_active Application Discontinuation
- 1995-10-04 NZ NZ295546A patent/NZ295546A/en unknown
- 1995-10-04 PL PL95319511A patent/PL319511A1/en unknown
- 1995-10-04 EP EP95938184A patent/EP0784474A2/en not_active Ceased
- 1995-10-04 HU HU9702291A patent/HUT77883A/en unknown
- 1995-10-04 KR KR1019970702223A patent/KR970705997A/en not_active Application Discontinuation
- 1995-10-04 AU AU38913/95A patent/AU702519B2/en not_active Ceased
- 1995-10-04 BR BR9509251A patent/BR9509251A/en not_active Application Discontinuation
- 1995-10-04 JP JP8512678A patent/JPH10507177A/en active Pending
- 1995-10-04 RU RU97107466/14A patent/RU2157687C2/en active
- 1995-10-04 CA CA002201628A patent/CA2201628A1/en not_active Abandoned
- 1995-10-04 CZ CZ971041A patent/CZ104197A3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ104197A3 (en) | 1997-09-17 |
| EP0784474A2 (en) | 1997-07-23 |
| WO1996011007A1 (en) | 1996-04-18 |
| JPH10507177A (en) | 1998-07-14 |
| RU2157687C2 (en) | 2000-10-20 |
| AU3891395A (en) | 1996-05-02 |
| NZ295546A (en) | 1999-01-28 |
| KR970705997A (en) | 1997-11-03 |
| PL319511A1 (en) | 1997-08-18 |
| AU702519B2 (en) | 1999-02-25 |
| BR9509251A (en) | 1997-10-21 |
| HUT77883A (en) | 1998-09-28 |
| MX9702473A (en) | 1997-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1052974B1 (en) | Pharmaceutical formulation containing epothilone | |
| JP5670335B2 (en) | Bendamustine liquid formulation | |
| EP2616076B1 (en) | Pharmaceutical compositions | |
| US10688111B2 (en) | Liquid formulations of compounds active at sulfonylurea receptors | |
| ES2451540T3 (en) | Oral dosage forms of bendamustine | |
| US11779585B2 (en) | Method for treating coronavirus infections | |
| BG66494B1 (en) | Processes for the preparation of pharamaceutical preparations containing epothilone analogues for the treatment of cancer | |
| AU702519B2 (en) | Parenteral pharmaceutical compositions containing GF120918A | |
| US7419996B2 (en) | Parenteral and oral formulations of benzimidazoles | |
| WO2016046786A1 (en) | Long acting pharmaceutical compositions | |
| US20230404918A1 (en) | Fulvestrant formulations and methods of their use | |
| US6683100B2 (en) | Organic compounds | |
| EP2310009B1 (en) | Parenteral and oral formulations of benzimidazoles | |
| KR101679380B1 (en) | Pharmaceutical composition including dutasteride and capsule formulation comprising the same | |
| EP1667656A1 (en) | Compositions and methods for delivery of biologically active agents | |
| AU2011273064A1 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| EP2588097A2 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| WO2018047074A1 (en) | Sterile injectable compositions comprising drug micelles | |
| RU2236227C1 (en) | Stable pharmaceutical formulation of anticancer preparation | |
| WO2012029076A2 (en) | Stable pharmaceutical composition | |
| MXPA97002473A (en) | Parenteral pharmaceutical compositions containing gf1209 | |
| CN1164189A (en) | Parenteral pharmaceutical compositions containing GF 120918A | |
| WO2021044328A1 (en) | Cabazitaxel liquid formulations | |
| WO2018109731A1 (en) | Pharmaceutical compositions of taxane and its derivatives | |
| AU2004267882A1 (en) | Compositions and methods for delivery of biologically active agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |